| Bioactivity | Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor[1]. | ||||||||||||
| Name | Dapagliflozin impurity | ||||||||||||
| CAS | 960404-86-8 | ||||||||||||
| Formula | C21H25ClO7 | ||||||||||||
| Molar Mass | 424.87 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kasichayanula S, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011 Jan;13(1):47-54. |
Dapagliflozin impurity
CAS: 960404-86-8 F: C21H25ClO7 W: 424.87
Dapagliflozin impurity is an enantiomer of Dapagliflozin which is a sodium-glucose transporter 2 inhibitor.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.